There appear to be genetic determinants of A1C (14), with differing degrees of hemoglobin glycation potentially related to differences in erythrocyte survival, different intracellular oxygen tension, 2,3-diphosphoglycerate levels, pH, or different degrees of erythrocyte permeability to glucose.
In clinical settings, the parameter of interest is the degree of hemoglobin oxygenation, termed tissue oxygen saturation (StO2).
The amount of O2 transferred depends on the blood flow through ILA and on the degree of hemoglobin desaturation in arterial blood.
The volume of O2 delivered depended on the shunt flow rate and the degree of hemoglobin desaturation and was rather small, on average not exceeding 17% of the total O2 consumption.
If future analyses of ACCORD are able to more fully take into account participants' home glucose measurements, show a relationship between weight gain and mortality, or show that mortality was associated with a higher degree of hemoglobin glycation for a given level of glycemia, it may be possible to gain a fuller understanding of these questions.
Routine blood testing showed varying degrees of low hemoglobin concentration, low plasma fibrinogen level, and prolonged prothrombin time.
These include the degree of glycosylated hemoglobin (HbA1c) reduction needed, risk of hypoglycemia, the side effects of medication, concomitant medical conditions, and the patient's ability to adhere to the medication regimen and their preferences.
One year later, the patient had the same degree of hemolysis (hemoglobin = 7.4 g/dl, LDH = 756 U/l, total bilirubin = 2.7 g/dl) though his creatinine clearance had decreased (69.5 ml/min).
In general, the amount of O2 that can be added into the bloodstream is expected to depend mainly on the flow rate and the degree of desaturation of hemoglobin (as the amount of physically dissolved O2 is rather low).
The following independent variables were considered for selection in the stepwise linear regression, using backwards selection: age, race, systolic BP, diastolic BP, glycated hemoglobin, degree of proteinuria, initial hemoglobin, and initial serum albumin level.
Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss.
